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OBJECTIVES We studied the effects of sildenafil, a phosphodiesterase 5 inhibitor, on coronary and
peripheral vascular function, platelet activation, and myocardial ischemia.
BACKGROUND Nitric oxide vasodilates and inhibits platelet activation by generating cyclic guanosine
5-monophosphate, which is metabolized by phosphodiesterase type 5.
METHODS The effect of oral sildenafil on resting coronary vascular tone, endothelium-dependent and
-independent function and platelet activation was measured in 24 patients. An additional 24
patients with coronary artery disease (CAD) and ischemia during exercise, and 12 control
subjects received either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo
during exercise on three separate days in a randomized, double-blind manner. Flow-mediated
dilation of the brachial artery was measured, and CAD patients underwent treadmill exercise
testing.
RESULTS Sildenafil (100 mg) vasodilated epicardial coronary arteries (6.9  1.3%, p  0.0001).
Coronary epicardial and microvascular responses with acetylcholine and cold-pressor testing
improved, with a greater enhancement in patients with CAD and endothelial dysfunction.
Verapamil responses were unchanged. Both resting and adenosine diphosphate-stimulated
platelet IIb/IIIa receptor activation was inhibited by sildenafil (p  0.05). Brachial arteries
dilated in response to sildenafil in controls. Peak flow-mediated dilation was similar, but the
duration of hyperemia was prolonged after sildenafil administration (p  0.001). Compared
with placebo, ISDN improved myocardial ischemia during exercise (p  0.05), whereas the
effect of sildenafil was intermediate between the two.
CONCLUSIONS Sildenafil dilates epicardial coronary arteries, improves endothelial dysfunction and inhibits
platelet activation in patients with CAD. It has an intermediate effect on myocardial ischemia
compared with ISDN and placebo. (J Am Coll Cardiol 2002;40:1232–40) © 2002 by the
American College of Cardiology Foundation
Endothelial nitric oxide (NO) modulates vascular tone at
rest, facilitates vasodilation during stress and inhibits plate-
let aggregation by activating intracellular guanylate cyclase,
which in turn generates cyclic guanosine 5-monophosphate
(cGMP) (1–7). Vascular smooth muscle cGMP levels are
regulated by the activity of phosphodiesterase type 5
(PDE5), and sildenafil citrate (Viagra Pfizer, Inc., New
York, New York), a highly selective antagonist of PDE5,
enhances the effect of NO in experimental models (8).
Because endothelial dysfunction is associated with vascular
inflammation, platelet activation and rapid progression of
atherosclerosis and its adverse events, strategies that en-
hance NO bioavailability may positively impact outcomes in
patients with coronary artery disease (CAD). We hypoth-
esized that PDE5 inhibition with sildenafil would abrogate
coronary and peripheral vascular endothelial dysfunction in
patients with CAD, inhibit platelet activation and amelio-
rate myocardial ischemia during stress.
METHODS
Protocols were approved by the Institutional Review Board
and informed written consent obtained.
Study 1. PATIENTS. We studied 24 patients with either
CAD (n  15) or with angiographically normal coronary
arteries (NCA, n  9) undergoing cardiac catheterization
for investigation of chest pain and/or abnormal noninvasive
cardiac investigations. CAD was defined as the presence of
plaquing (n  2) or significant stenosis 50% in one (n 
7) or two (n  6) epicardial coronary arteries. Mean age of
the patients was 54  2 years, and mean cholesterol level
was 191  8 mg/dl. Twenty-two were male,11 had hyper-
tension, 6 were smokers and 6 were diabetic. Fifteen were
on statin therapy, and those with recent acute coronary
syndromes were excluded. Aspirin and angiotensin-
converting enzyme inhibitors were withheld for at least
seven days, and other cardiac medications were discontinued
for 5 half-lives before the study. A low nitrate diet was
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maintained for 24 h before the study, and nitrovasodilators
were withheld for 24 h before and after the procedure.
PROTOCOL. After diagnostic coronary angiography, a 3F
infusion catheter was introduced into a coronary artery
without significant stenosis (20%) and blood flow velocity
was measured using a 0.014-inch wire equipped with a
Doppler crystal at its tip (FloWire, EndoSonics, Rancho
Cordova, California). Coronary blood flow was derived
from the velocity and diameter measurements using the
formula (  average peak velocity  0.25  diameter2) as
described previously (9). Coronary vascular resistance
(CVR) was derived as mean arterial blood pressure divided
by coronary blood flow (2).
After baseline measurements, cold-pressor testing (CPT)
was performed by immersing the hand in ice-cold water for
90 to 120 s. After recovery, endothelium-dependent coro-
nary vasomotion was estimated using 2-min infusions of
acetylcholine (ACH) at 1.5 and 15 g/min (estimated
intracoronary concentrations of 107 mol/l and 106 mol/l,
respectively), and endothelium-independent function was
determined using intracoronary verapamil at 300 g/min
for 2 min. Patients were given 100 mg of sildenafil orally,
and after 45 min, when its peak hemodynamic effects occur,
CPT was repeated and ACH and verapamil were readmin-
istered (10).
Systemic, pulmonary and coronary vascular hemodynam-
ics were recorded and coronary angiography was performed
after each intervention. Epicardial diameter was measured
in segments free of overlap, severe tapering or bifurcations
using quantitative angiography (CAAS II, Pie Medical,
Maastricht, Netherlands; 3 segments were analyzed in 12,
and 2 segments in 12 patients) by an investigator who had no
knowledge of the study sequence. In addition, to investigate
the effect of sildenafil on stenotic atherosclerotic segments, we
measured minimum lumen diameter in segments ranging from
20% to 40% stenosis (n  6) that were present in epicardial
arteries neighboring the study vessel. Central venous blood was
obtained at baseline and 45 min after sildenafil for platelet flow
cytometry in 16 subjects (10 with CAD).
REPRODUCIBILITY STUDIES. Reproducibility of coronary
vascular changes with these interventions were assessed in
six patients in whom ACH and verapamil infusions and
CPT were repeated after 45 min. Epicardial diameter
responses with ACH 15 g/min (2.13  0.2 to 2.24  0.2
mm, r  0.97), verapamil 300 g/min (2.45  0.2 to 2.47
 0.2 mm, r  0.99) and CPT (1.93  0.2 to 1.92  0.2
mm, r  0.96) were reproducible after 45 min. Similarly,
CVR responses with ACH (r  0.91), verapamil (r  0.99)
and CPT (r  0.76) were also reproducible.
PLATELET FLOW CYTOMETRY. Immediately after with-
drawal, aliquots of 450 l citrated venous whole blood were
mixed with 50 l of either phosphate-buffered saline, 200
mol/l ADP solution (Bio/Data Corp., Horsham, Penn-
sylvania) or 100 mol/l TRAP (Biosearch, New Brunswick,
New Jersey). Two 5-l aliquots were added to tubes
containing saturating concentrations of either FITC-labeled
PAC-1, PE-labeled CD-62 and Per-CP–labeled CD-
61(Becton Dickinson Immunocytometry Systems, San Jose,
California) with RGDS (Sigma, St. Louis, Missouri) as a
competitive inhibitor of PAC-1 binding or FITC-labeled
PAC-1, PE-labeled mouse anti-human IgG1 (Beckman
Coulter, Inc., Fullerton, California.) and Per-CP–labeled
CD-61. Samples were fixed in paraformaldehyde solution
and analyzed within 24 h on a FACScan flow cytometer
(Becton Dickinson). The percentage of platelets positive for
PAC-1 (representing activated IIb/IIIa receptor) or CD-62
(representing surface expression of P-selectin, a marker of
-granule release) were calculated from 10,000 events pos-
itive for the platelet-specific antibody CD-61 that bound
PAC-1-FITC or CD-62-PE antibodies with a fluorescent
intensity greater than a threshold set at 1% from the
respective negative control sample.
Study 2. PATIENTS. Twelve healthy volunteers, eight male,
aged 32  2 years and 24 patients with asymptomatic or
mildly symptomatic stable CAD who developed 1 mm
ST-segment depression on exercise were studied after dis-
continuation of all medications for at least five half-lives. Six
patients with CAD had single, nine had two-vessel and nine
had three-vessel disease. All patients had exercise-induced
reversible myocardial perfusion defects. Mean age was 65 
2 years, 22 were male, 12 were hypertensive, 2 were
smokers, 9 were diabetic and 21 were on statin therapy, with
a mean cholesterol level of 187  9 mg/dl.
PROTOCOL. The study was performed on 3 separate days
when subjects received either 100 mg of sildenafil, 10 mg of
isosorbide dinitrate (ISDN) or placebo in a double-blind,
randomized, placebo-controlled manner. Each morning
after an overnight fast, subjects underwent vascular reactiv-
ity studies before and 45 min after the study drug. CAD
patients also underwent treadmill exercise testing 1 h after
receiving the study medication.
FLOW-MEDIATED VASODILATION (FMD). Two-dimensional
images of the brachial artery were obtained above the
antecubital crease using a 12.5-MHz linear array ultrasound
transducer (ATL HDI 5000 cv, Andover, Massachusetts).
Diameter (D) was measured at baseline and after 60 s of
Abbreviations and Acronyms
ACH  acetylcholine
CAD  coronary atherosclerosis
cGMP  cyclic guanosine monophosphate
CPT  cold-pressor testing
CVR  coronary vascular resistance
D  diameter
FMD  flow-mediated dilation
ISDN  isosorbide dinitrate
PDE5  phosphodiesterase type V
NCA  normal coronary arteries
NO  nitric oxide
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hyperemia in all patients and after 80 s, 2 min, 2.5 min, 3
min, 3.5 min and 4 min in 16 subjects (eight patients and
eight controls) (11). Measurements were repeated 45 min
after the study drug. Analysis was performed in a blinded
manner by a single observer. The intra-observer correlation
for repeated measurements of D in our laboratory is 0.98
(mean 3.64  0.24 and 3.60  0.2 mm).
TREADMILL EXERCISE TESTING. Patients with CAD un-
derwent symptom-limited, maximal treadmill exercise, us-
ing the National Institutes of Health Combined protocol,
immediately after completion of the vascular reactivity study
(12). Heart rate, blood pressure and 12-lead electrocardio-
gram (ECG) were recorded every 30 s during the exercise
period. All patients underwent exercise testing on at least
two previous occasions to ensure reproducibility and famil-
iarity.
STATISTICAL ANALYSIS. Means were compared by paired or
unpaired Student t test. Dose–response curves with ACH
were compared by repeated measures analysis of variance
(ANOVA, SAS, Version 6.12; Cary, North Carolina: SAS
Institute,1996). If the F value was significant, Bonferroni
multiple comparison tests were performed. The effect of
sildenafil on FMD from the 60-s to 4-min time points was
studied by the repeated measures ANOVA model, includ-
ing patients, medication (sildenafil and pre-sildenafil), pres-
ence or absence of CAD and time as main effects and
incorporating the two factor interactions between them.
Data are expressed as mean  SEM, and all p values are
two-tailed. Multiple stepwise regression analysis was per-
formed to establish the most parsimonious model for the
relationship between the magnitude of change in epicardial
diameter with sildenafil and the covariates age, gender, race,
presence of CAD, hypertension, diabetes, current cigarette
use, total cholesterol, low-density and high-density lipopro-
tein and triglyceride levels.
RESULTS
Study 1: systemic and pulmonary hemodynamic ef-
fects. Supine mean pulmonary arterial and wedge pressures
fell by 13  3% and 18  6%, respectively, after sildenafil
but systemic and pulmonary vascular resistance, mean su-
pine blood pressure, heart rate and cardiac output were
unchanged (Table 1).
Resting coronary vascular tone. EPICARDIAL CIRCULA-
TION. Significant epicardial vasodilation occurred 30 min
after sildenafil, reaching a maximum of 6.9  1.3% after 45
min (p  0.0001) (Fig. 1). Vasodilation was similar in
patients with and without CAD (5.6  1.1%, p  0.0001
and 7.4  1.8%, p  0.001, respectively) and in mid- and
distal epicardial segments. In comparison, verapamil pro-
duced 8.4  1.1% vasodilation before sildenafil. Stenotic
segments of coronary arteries dilated by 13.3% in response
to sildenafil, from 1.41  0.12 to 1.57  0.57 mm, p 
0.03. Increasing age, but not the presence of CAD, was an
independent predictor of the epicardial response to silde-
nafil, (p  0.05 by multivariate analysis).
MICROVASCULAR CIRCULATION. Coronary blood flow (p
0.15) and CVR (p  0.26) remained unchanged after
sildenafil in all groups (Table 2).
Coronary vascular endothelial function. EPICARDIAL
CIRCULATION. Epicardial coronary diameter with ACH
was greater after sildenafil was administered (p  0.001,
ANOVA) but not after verapamil (p 0.17) (Table 2). The
response was separately assessed in epicardial segments that
initially constricted (denoting endothelial dysfunction) and
those that dilated (normal endothelial function) with ACH.
Segments with constriction but not those that initially
dilated with ACH improved after sildenafil (Fig. 2). Simi-
larly, patients with CAD had tended to exhibit an improve-
ment in their epicardial coronary responses (from 1.3 
Table 1. Hemodynamic Effects
Baseline 45 Min Post-Sildenafil
Study 1
Pulmonary arterial pressure (mm Hg) 17.0  1.0 14.7  1.0‡
Pulmonary wedge pressure (mm Hg) 9.4  0.8 7.6  0.8†
Pulmonary vascular resistance (dynes.s.cm5) 119.2  8.8 109.6  11.2
Cardiac output (l/min) 5.2  0.3 5.4  0.3
Mean arterial pressure (mm Hg) 103  2 101  3
Systemic vascular resistance (dynes.s.cm5) 1,680  88 1,552  80
Heart rate (beats/min) 69  2 70  2
Controls Patients
Placebo Sildenafil Isosorbide Placebo Sildenafil Isosorbide
Study 2
HR (beats/min) 57  3 62  4* 60  3 61  2 63  2 69  3§
SBP (mm Hg) 110  4 109  3 104  6 141  4 129  4* 120  4*§
DBP (mm Hg) 67  2 62  2* 62  2* 81  2 72  2* 70  2*
MBP (mm Hg) 81  3 77  2* 76  3* 101  3 91  2* 89  2*§
†p  0.01, ‡p  0.001 vs. baseline. *p  0.05 vs. placebo, §p  0.05 vs. sildenafil.
DBP  diastolic blood pressure; HR  heart rate; MBP  mean systemic blood pressure; SBP  systolic blood pressure.
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2.8% to 0.4  3% with 15 g/min of ACH, p  0.07), but
this was not observed in those with NCA (p  0.3).
To assess endothelial function with ACH independent of
the baseline dilator effect of sildenafil, we calculated the
ratio of epicardial diameter with ACH/verapamil before and
after sildenafil was administered. There was a significant
improvement in the epicardial ACH/verapamil ratio after
sildenafil administration (p  0.0001 by ANOVA).
MICROVASCULAR CIRCULATION. ACH and verapamil in-
fusions at baseline produced progressive microvascular dila-
tion (Table 2). After sildenafil administration, CVR with
ACH was lower (p  0.03, ANOVA) but not with
verapamil (p  0.9), indicating selective improvement in
microvascular endothelium-dependent function (Table 2,
Fig. 3). In patients with CAD, ACH-mediated microvas-
cular dilation was enhanced (p  0.013, ANOVA for
percentage of change in CVR), whereas it remained un-
changed in those with NCA (Fig. 3).
Coronary vascular response to CPT epicardial circula-
tion. The heart rate during CPT was similar (77 8 before
vs. 78  3 beats/min after sildenafil) but increase in blood
pressure was lower after sildenafil (132 4 before vs. 122
4 mm Hg after, p  0.04). Coronary epicardial diameter
during CPT was greater after sildenafil (from 1.92  0.1
mm pre- to 2.04  0.1 mm, p  0.001). This dilation was
observed in patients with and without CAD (p  0.01 in
both). To assess the response to CPT independent of the
baseline dilator effect of sildenafil, we calculated the epicar-
dial diameter ratio of CPT/verapamil before and after
sildenafil. There was a significant improvement in the
CPT/verapamil ratio after sildenafil (p  0.001) (Fig. 4).
MICROVASCULAR CIRCULATION. There was no coronary
microvascular dilation observed during CPT at baseline (5.5
 3.6% change in CVR). After sildenafil, there was signif-
icant microvascular vasodilation with CPT (2.3  3% fall
in CVR, p  0.02) (Fig. 4).
Platelet flow cytometry. The percent of platelets positive
for PAC-1 expression in the unstimulated (7.7  2% to 4.4
 1%, p 0.04) and ADP-stimulated samples (85 3% to
67 5%, p 0.008) were significantly lower after sildenafil
but remained unchanged with TRAP stimulation (Fig. 5).
Sildenafil therapy did not significantly alter the percentage
of platelets positive for CD-62 with and without ADP or
TRAP (data not shown).
Study 2: resting hemodynamics. CONTROLS. Mean and
diastolic blood pressure were lower with both ISDN and
sildenafil compared with placebo (Table 1).
CAD PATIENTS. Heart rate increased with ISDN compared
with both sildenafil and placebo. Systolic and diastolic blood
pressures fell with ISDN and sildenafil, with the effect of
ISDN being greater (Table 1).
Treadmill exercise. ISCHEMIC THRESHOLD. Compared
with placebo, ISDN improved time-to and rate-pressure
product at 1 mm of ST depression (both p  0.05).
Sildenafil had an intermediate effect with no significant
difference compared with either ISDN or placebo (Table 3).
PEAK EXERCISE. There was no difference in total exercise
time or rate-pressure product at peak exercise between the
three treatment periods. However, ST depression at peak
exercise was lower with ISDN compared with placebo
(Table 3). Sildenafil had an intermediate effect on this
Figure 1. Effect of sildenafil (100 mg PO) on epicardial coronary diameter
in all patients and the subsets with and without coronary atherosclerosis
(CAD).
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parameter (Table 3). Rate-pressure product at each stage of
exercise was similar in the three study groups. No significant
arrhythmia or hemodynamic disturbance was observed.
CHEST PAIN. Twelve patients (50%) experienced chest pain
during treadmill exercise when administered placebo, six
(25%) when administered ISDN and seven (29%) when
administered sildenafil (p  NS between groups).
Resting brachial artery diameter. CONTROLS. Brachial
arteries dilated from 3.39 0.23 to 3.54 0.22 mm (4.8
1.6%, p  0.01) after sildenafil and to 4.18  0.21 mm (23
 2%, p  0.001) after ISDN.
CAD PATIENTS. ISDN dilated the brachial artery by 18 
2%, p  0.001 (from 3.67  0.11 to 4.38  0.11 mm), but
D was unchanged (3.8  0.1 mm) after sildenafil (1.6 
0.9%, p  0.12 vs. baseline and p  0.06 vs. controls).
Brachial artery dilation was greater with ISDN compared to
sildenafil in both groups. The D remained unchanged with
placebo.
EFFECT ON FMD PEAK. FMD at 60 s was unchanged by
placebo and ISDN in both groups. Peak FMD was un-
changed by sildenafil in both controls (8.7  1.8% before
vs.8.4 1.7% after, pNS) and in CAD patients (6.8
 1.0% before vs. 6.2  0.9% after, p  NS).
Hyperemic vasodilation of the brachial artery persisted
for a significantly longer duration after sildenafil compared
to pre-sildenafil; by ANOVA, a significant interaction with
time was noted, with higher D after sildenafil between 2.5
and 4 min of hyperemia (p  0.05) (Fig. 6). Similar effects
were noted in subjects with and without CAD.
DISCUSSION
We have investigated the effects of sildenafil on human
coronary and peripheral circulation, on platelet function,
and on myocardial ischemia in patients with CAD with the
hypothesis that increased NO-mediated cGMP availability
will improve vascular and platelet function and ameliorate
myocardial ischemia. We demonstrated that 100 mg of oral
sildenafil produces epicardial coronary arterial vasodilation
in patients with CAD and in those with NCA who exhibit
risk factors. This effect was observed in smooth and mildly
atherosclerotic segments of the coronary arteries. Brachial
arterial vasodilation was observed with sildenafil in healthy
controls but not in patients with CAD. Sildenafil also
selectively improved endothelium-dependent coronary vas-
cular responses and vasomotion during physiologic stress
without affecting endothelium-independent responses. This
effect was greater in patients with CAD and those with
endothelial dysfunction. Consistent with these findings,
prolongation of peripheral vasodilation was observed during
hyperemia.
The impact of sildenafil on patients’ ischemic threshold
during exercise was modest, with an effect that was inter-
Table 2. Coronary Vascular Effects of Sildenafil
Baseline S ACH 1 ACH1  S ACH2 ACH2  S Verapamil Verapamil  S
Coronary blood flow (ml/min) 39.5  5 41.8  5 48.9  6 57.8  8† 91.9  12 94.4  14 72.8  12 71  12
Coronary vascular resistance 3.5  0.4 3.4  0.4 3.5  0.4 2.3  0.3* 1.6  0.2 1.5  0.2* 2.0  0.4 2.0  0.5
Diameter (mm) 1.99  0.08 2.12  0.08‡ 1.97  0.08 2.10  0.09‡ 1.95  0.08 2.1  0.09‡ 2.2  1 2.2  0.1
Coronary blood flow, vascular resistance, and diameter were significantly different pre- vs. post-sildenafil (S) by ANOVA (p  0.05). *p  0.05, †p  0.01, ‡p  0.001 pre-
vs. post-sildenafil (S). Vascular resistance is (mm Hg/ml/min).
ACH  acetylcholine (ACH1  1.5 and ACH2  15 g/min dose); S  sildenafil.
Figure 2. Effect of sildenafil on percent of change in epicardial coronary artery diameter in segments that were initially constricted with acetylcholine
(denoting endothelial dysfunction) and those that were initially dilated with acetylcholine (preserved endothelial function).
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mediate between placebo and a 10 mg of oral ISDN. No
patient experienced significant exacerbation of exercise-
induced ischemia or cardiac arrhythmia with sildenafil.
Coronary, pulmonary, and systemic effects. A small fall
in supine pulmonary and seated systemic arterial pressures
confirmed the previously reported mild vasodilator activity
of sildenafil (10,13). The smaller fall in arterial pressure
observed with sildenafil in the catheterization study may be
explained by the subjects’ supine position rather than time
to peak onset of the drug effect because significant pulmo-
nary and epicardial coronary vasodilation were observed.
The effects of sildenafil on blood pressure and heart rate
were less compared with 10 mg of ISDN in patients with
CAD. To our knowledge, this is the first demonstration of
human epicardial coronary vasodilation by sildenafil in
patients with and without CAD in vivo and confirms
previous observations in porcine coronary arteries (14). The
lack of epicardial vasodilation observed in a previous study
may have been due to differences in quantitative angio-
graphic techniques or to the confounding effects of concom-
itant cardiac medications (13). The magnitude of epicardial
dilation with sildenafil was approximately a third of that
observed with nitroglycerin (15) and similar to that observed
with verapamil. The apparent greater percent of dilation of
mildly stenotic segments was not significantly different from
smooth segments. Peripheral conduit arterial vasodilation
with sildenafil was less marked than in the coronary arteries,
which may be due to differences in patient selection.
However, it is likely that the vasodilator response to PDE5
antagonism is proportional to basal production of NO and
differences in basal NO activity between these circulations
may provide an explanation (3,4,16,17). Similarly, the lack
of vasodilation of the brachial arteries in CAD patients
compared to controls may have been due to differences in
age and/or tonic NO activity.
Endothelium-dependent vascular function. Acetylcho-
line vasoconstricts vessels with dysfunctional endothelium
because the constrictor effect of smooth muscle muscarinic
Figure 3. Effect of sildenafil on microvascular vasodilation (percent of change in coronary vascular resistance [CVR] as a result of acetylcholine and
verapamil in all patients and in response to acetylcholine in patients with and without angiographic coronary atherosclerosis (CAD).
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receptor activation predominates over the dilating effects of
endothelium-derived relaxing factors, in particular NO
(2,18,19). We observed selective improvement in ACH
responses independent of the response to verapamil, denot-
ing improvement in endothelial function, which was con-
sistent with findings in canine experiments (20). A greater
enhancement of endothelial function occurred in patients
with CAD and those with more severe endothelial dysfunc-
tion. Because inhibition of NO synthase abolishes PDE5
antagonist-mediated vasodilation, potentiation of cGMP
almost certainly explains our observations (21,22).
An important consequence of endothelial dysfunction is
the resulting abnormal vasomotion during physiologic
stresses such as exercise, pacing or exposure to cold, believed
to be due to reduced shear-mediated NO release (3,23–26).
Improvement in coronary vasomotion during CPT after
sildenafil extends observations we made during pharmaco-
logic testing. They are also consistent with previously
reported improvement in coronary flow reserve with aden-
osine in subjects with CAD and enhancement of FMD in
heart failure after sildenafil treatment (13,27).
Our findings in the brachial artery confirmed observa-
tions made in the coronary circulation. FMD, a largely
NO-dependent phenomenon, was prolonged by sildenafil,
without affecting maximal vasodilation (4).
Exertional myocardial ischemia. As expected, indices of
ischemia improved after ISDN. A modest improvement was
observed after sildenafil, but their magnitude was not
Figure 4. (A) Effect of sildenafil on epicardial coronary artery diameter ratio cold-pressor testing (CPT)/verapamil. (B) Effect of sildenafil on microvascular
vasodilation (reduction in coronary vascular resistance) during CPT. Black bars  pre-sildenafil; white bars  post-sildenafil.
Figure 5. Effect of sildenafil on surface expression of activated platelet glycoprotein IIb/IIIa receptors illustrated by the percentage of platelets binding
FITC-conjugated PAC-1 antibodies. ADP  adenosine diphosphate; TRAP  thrombin receptor activator peptide. Black bars  pre-sildenafil; white
bars  post-sildenafil. *p  0.05, **p  0.01, NS  not significant.
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significantly different compared to either placebo or ISDN,
a finding that is consistent with the lower vasodilator
potency of sildenafil compared to nitroglycerin on resting
vascular tone (15).
Platelet activation. We have previously reported that en-
dogenous NO importantly contributes to platelet passiva-
tion in vivo in the human coronary and peripheral circula-
tions (6,7). Here, we examined the effect of sildenafil on two
markers of platelet activation that reflect activated platelet
glycoprotein IIb/IIIa receptor (PAC-1 antibody binding)
and surface expression of P-selectin (CD-62 antibody bind-
ing) a marker of alpha-granule release (28,29). We observed
reduced binding of PAC-1 in the unstimulated and ADP-
stimulated whole blood whereas CD-62 binding was not
significantly altered by sildenafil, suggesting increased
threshold for activation of the IIb/IIIa receptor without an
effect on platelet degranulation (30,31). This is also consis-
tent with potentiation of the anti-aggregatory action of NO
donors by sildenafil reported previously (29,32). Whether
the observed anti-platelet effect results in a clinically rele-
vant benefit requires further investigation.
Study limitations. We examined the effect of a single dose
of sildenafil; however, its action after multiple dosages may
vary. Study 1 was not placebo-controlled because of the
invasive nature of the protocol, but the analysis was blinded.
The trend toward an improvement in exercise-induced isch-
emia with sildenafil compared with placebo is consistent with
our observation of improved physiologic coronary vasomotion
and also its known beneficial effect on coronary flow reserve
(13). However, this may only reach statistical significance in a
larger study population. It may not be reasonable to extend our
findings to very symptomatic or unstable patients with CAD,
and interactions with the sympathetic nervous system or other
cardiac medications were also not investigated (33).
Conclusions. Sildenafil dilates epicardial coronary arteries,
improves endothelial dysfunction, and improves physiologic
coronary vasomotion, suggesting that PDE5 antagonism
has a potential role in the treatment of patients with vascular
endothelial dysfunction. Furthermore, sildenafil attenuates
activation of the platelet IIb/IIIa receptor, and its anti-
ischemic effect was intermediate between ISDN and pla-
cebo. Further studies are required to determine the clinical
impact of these observations.
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Table 3. Study 2: Effects of Placebo, Sildenafil, and Isosorbide Dinitrate on Exercise Parameters
Placebo Sildenafil Isosorbide
Exercise duration to ischemic threshold (s) 538  63 563  62 598  68*
Peak exercise duration (s) 687  50 692  57 710  53
Heart rate (beats/min) 140  3 142  4 139  3
Systolic blood pressure (mm Hg) 164  5 159  5 165  5
Diastolic blood pressure (mm Hg) 78  2 73  3 71  3
RPP at ischemic threshold (103 mm Hg.beats/min) 19.0  0.8 20.6  0.8 21.9  0.8*
RPP at peak exercise (103 mm Hg.beats/min) 22.8  0.8 22.6  0.9 22.9  0.8
Maximum ST depression (mm) 1.77  0.20 1.55  0.16 1.52  0.18*
Ischemic threshold is at onset of 1-mm ST segment depression. *p  0.05 vs. placebo.
RPP  rate-pressure product.
Figure 6. Flow-mediated vasodilation (percent of change in diameter of the brachial artery compared with baseline) is shown during hyperemia, before and
after sildenafil. Filled circles  pre-sildenafil; open circles  post-sildenafil.*p  0.05 pre- vs. post-sildenafil.
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